Search

Your search keyword '"Mariathasan, Sanjeev"' showing total 345 results
Start Over Author "Mariathasan, Sanjeev"
345 results on '"Mariathasan, Sanjeev"'

1. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Author

Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., and Patil, Namrata S.

Published
2024
Full Text
View/download PDF

2. Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Author

Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., and Patil, Namrata S.

Published
2024
Full Text
View/download PDF

3. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade

Author

Hamidi, Habib, Senbabaoglu, Yasin, Beig, Niha, Roels, Juliette, Manuel, Cyrus, Guan, Xiangnan, Koeppen, Hartmut, Assaf, Zoe June, Nabet, Barzin Y., Waddell, Adrian, Yuen, Kobe, Maund, Sophia, Sokol, Ethan, Giltnane, Jennifer M., Schedlbauer, Amber, Fuentes, Eloisa, Cowan, James D., Kadel, Edward E., III, Degaonkar, Viraj, Andreev-Drakhlin, Alexander, Williams, Patrick, Carter, Corey, Gupta, Suyasha, Steinberg, Elizabeth, Loriot, Yohann, Bellmunt, Joaquim, Grivas, Petros, Rosenberg, Jonathan, van der Heijden, Michiel S., Galsky, Matthew D., Powles, Thomas, Mariathasan, Sanjeev, and Banchereau, Romain

Published
2024
Full Text
View/download PDF

4. Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Author

Guan, Xiangnan, Hu, Ruozhen, Choi, Yoonha, Srivats, Shyam, Nabet, Barzin Y., Silva, John, McGinnis, Lisa, Hendricks, Robert, Nutsch, Katherine, Banta, Karl L., Duong, Ellen, Dunkle, Alexis, Chang, Patrick S., Han, Chia-Jung, Mittman, Stephanie, Molden, Nandini, Daggumati, Pallavi, Connolly, Wendy, Johnson, Melissa, Abreu, Delvys Rodriguez, Cho, Byoung Chul, Italiano, Antoine, Gil-Bazo, Ignacio, Felip, Enriqueta, Mellman, Ira, Mariathasan, Sanjeev, Shames, David S., Meng, Raymond, Chiang, Eugene Y., Johnston, Robert J., and Patil, Namrata S.

Published
2024
Full Text
View/download PDF

5. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer

Author

Galsky, Matthew D., Guan, Xiangnan, Rishipathak, Deepali, Rapaport, Aaron S., Shehata, Hesham M., Banchereau, Romain, Yuen, Kobe, Varfolomeev, Eugene, Hu, Ruozhen, Han, Chia-Jung, Li, Haocheng, Liang, Yuxin, Vucic, Domagoj, Wang, Li, Zhu, Jun, Yu, Haocheng, Herbst, Rebecca H., Hajaj, Emma, Kiner, Evgeny, Bamias, Aristotelis, De Santis, Maria, Davis, Ian D., Arranz, José Ángel, Kikuchi, Eiji, Bernhard, Sandrine, Williams, Patrick, Lee, Chooi, Mellman, Ira, Sanjabi, Shomyseh, Johnston, Robert, Black, Peter C., Grande, Enrique, and Mariathasan, Sanjeev

Published
2024
Full Text
View/download PDF

6. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

Author

Powles, Thomas, Assaf, Zoe June, Degaonkar, Viraj, Grivas, Petros, Hussain, Maha, Oudard, Stephane, Gschwend, Jürgen E., Albers, Peter, Castellano, Daniel, Nishiyama, Hiroyuki, Daneshmand, Siamak, Sharma, Shruti, Sethi, Himanshu, Aleshin, Alexey, Shi, Yi, Davarpanah, Nicole, Carter, Corey, Bellmunt, Joaquim, and Mariathasan, Sanjeev

Published
2024
Full Text
View/download PDF

7. In situ tumour arrays reveal early environmental control of cancer immunity

Author

Ortiz-Muñoz, Guadalupe, Brown, Markus, Carbone, Catherine B., Pechuan-Jorge, Ximo, Rouilly, Vincent, Lindberg, Henrik, Ritter, Alex T., Raghupathi, Gautham, Sun, Qianbo, Nicotra, Tess, Mantri, Shreya R., Yang, Angela, Doerr, Jonas, Nagarkar, Deepti, Darmanis, Spyros, Haley, Benjamin, Mariathasan, Sanjeev, Wang, Yulei, Gomez-Roca, Carlos, de Andrea, Carlos Eduardo, Spigel, David, Wu, Thomas, Delamarre, Lelia, Schöneberg, Johannes, Modrusan, Zora, Price, Richard, Turley, Shannon J., Mellman, Ira, and Moussion, Christine

Published
2023
Full Text
View/download PDF

8. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Author

Grande, Enrique, Arranz, José Á, De Santis, Maria, Bamias, Aristotelis, Kikuchi, Eiji, del Muro, Xavier Garcia, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Schutz, Fabio A, Puente, Javier, Li, Jian-Ri, O'Donnell, Peter H, Kalebasty, Arash Rezazadeh, Ye, Dingwei, Mariathasan, Sanjeev, Bene-Tchaleu, FabioIa, Bernhard, Sandrine, Lee, Chooi, Davis, Ian D, and Galsky, Matthew D

Published
2024
Full Text
View/download PDF

9. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Author

Bamias, Aristotelis, Davis, Ian D, Galsky, Matthew D, Arranz, José Á, Kikuchi, Eiji, Grande, Enrique, del Muro, Xavier Garcia, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Schutz, Fabio A, Puente, Javier, Li, Jian-Ri, Panni, Stefano, Gumus, Mahmut, Özgüroğlu, Mustafa, Mariathasan, Sanjeev, Poloz, Yekaterina, Bene-Tchaleu, Fabiola, Lee, Chooi, Bernhard, Sandrine, and De Santis, Maria

Published
2024
Full Text
View/download PDF

10. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Author

Bellmunt, Joaquim, Hussain, Maha, Gschwend, Jürgen, Albers, Peter, Oudard, Stephane, Castellano, Daniel, Daneshmand, Siamak, Nishiyama, Hiroyuki, Majchrowicz, Martin, Degaonkar, Viraj, Shi, Yi, Mariathasan, Sanjeev, Grivas, Petros, Drakaki, Alexandra, ODonnell, Peter, Rosenberg, Jonathan, Geynisman, Daniel, Petrylak, Daniel, Hoffman-Censits, Jean, Bedke, Jens, Kalebasty, Arash, Zakharia, Yousef, van der Heijden, Michiel, Sternberg, Cora, Davarpanah, Nicole, and Powles, Thomas

Subjects
Adolescent, Adult, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Carcinoma, Transitional Cell, Cisplatin, Disease-Free Survival, Female, Humans, Male, Middle Aged, Muscles, Neoplasm Invasiveness, Progression-Free Survival, Urothelium
Abstract

BACKGROUND: Despite standard curative-intent treatment with neoadjuvant cisplatin-based chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial carcinoma has a high recurrence rate and no level 1 evidence for adjuvant therapy. We aimed to evaluate atezolizumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma. METHOD: In the IMvigor010 study, a multicentre, open-label, randomised, phase 3 trial done in 192 hospitals, academic centres, and community oncology practices across 24 countries or regions, patients aged 18 years and older with histologically confirmed muscle-invasive urothelial carcinoma and an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 were enrolled within 14 weeks after radical cystectomy or nephroureterectomy with lymph node dissection. Patients had ypT2-4a or ypN+ tumours following neoadjuvant chemotherapy or pT3-4a or pN+ tumours if no neoadjuvant chemotherapy was received. Patients not treated with neoadjuvant chemotherapy must have been ineligible for or declined cisplatin-based adjuvant chemotherapy. No post-surgical radiotherapy or previous adjuvant chemotherapy was allowed. Patients were randomly assigned (1:1) using a permuted block (block size of four) method and interactive voice-web response system to receive 1200 mg atezolizumab given intravenously every 3 weeks for 16 cycles or up to 1 year, whichever occurred first, or to observation. Randomisation was stratified by previous neoadjuvant chemotherapy use, number of lymph nodes resected, pathological nodal status, tumour stage, and PD-L1 expression on tumour-infiltrating immune cells. The primary endpoint was disease-free survival in the intention-to-treat population. Safety was assessed in patients who either received at least one dose of atezolizumab or had at least one post-baseline safety assessment. This trial is registered with ClinicalTrials.gov, NCT02450331, and is ongoing but not recruiting patients. FINDINGS: Between Oct 5, 2015, and July 30, 2018, we enrolled 809 patients, of whom 406 were assigned to the atezolizumab group and 403 were assigned to the observation group. Median follow-up was 21·9 months (IQR 13·2-29·8). Median disease-free survival was 19·4 months (95% CI 15·9-24·8) with atezolizumab and 16·6 months (11·2-24·8) with observation (stratified hazard ratio 0·89 [95% CI 0·74-1·08]; p=0·24). The most common grade 3 or 4 adverse events were urinary tract infection (31 [8%] of 390 patients in the atezolizumab group vs 20 [5%] of 397 patients in the observation group), pyelonephritis (12 [3%]) vs 14 [4%]), and anaemia (eight [2%] vs seven [2%]). Serious adverse events occurred in 122 (31%) patients who received atezolizumab and 71 (18%) who underwent observation. 63 (16%) patients who received atezolizumab had a treatment-related grade 3 or 4 adverse event. One treatment-related death, due to acute respiratory distress syndrome, occurred in the atezolizumab group. INTERPRETATION: To our knowledge, IMvigor010 is the largest, first-completed phase 3 adjuvant study to evaluate the role of a checkpoint inhibitor in muscle-invasive urothelial carcinoma. The trial did not meet its primary endpoint of improved disease-free survival in the atezolizumab group over observation. Atezolizumab was generally tolerable, with no new safety signals; however, higher frequencies of adverse events leading to discontinuation were reported than in metastatic urothelial carcinoma studies. These data do not support the use of adjuvant checkpoint inhibitor therapy in the setting evaluated in IMvigor010 at this time. FUNDING: F Hoffmann-La Roche/Genentech.

Published
2021

11. Molecular determinants of response to PD-L1 blockade across tumor types

Author

Banchereau, Romain, Leng, Ning, Zill, Oliver, Sokol, Ethan, Liu, Gengbo, Pavlick, Dean, Maund, Sophia, Liu, Li-Fen, Kadel, Edward, Baldwin, Nicole, Jhunjhunwala, Suchit, Nickles, Dorothee, Assaf, Zoe June, Bower, Daniel, Patil, Namrata, McCleland, Mark, Shames, David, Molinero, Luciana, Huseni, Mahrukh, Sanjabi, Shomyseh, Cummings, Craig, Mellman, Ira, Mariathasan, Sanjeev, Hegde, Priti, and Powles, Thomas

Subjects
Human Genome, Lung, Clinical Research, Lung Cancer, Genetics, Cancer, Good Health and Well Being, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Cyclin-Dependent Kinase Inhibitor p16, Gene Expression Regulation, Neoplastic, Humans, Immune Checkpoint Inhibitors, Kidney Neoplasms, Lung Neoplasms, Mutation, Treatment Outcome, Urinary Bladder Neoplasms, Whole Genome Sequencing
Abstract

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical responses in subsets of cancer patients across multiple indications, including non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and renal cell carcinoma (RCC). Herein, we complement PD-L1 immunohistochemistry (IHC) and tumor mutation burden (TMB) with RNA-seq in 366 patients to identify unifying and indication-specific molecular profiles that can predict response to checkpoint blockade across these tumor types. Multiple machine learning approaches failed to identify a baseline transcriptional signature highly predictive of response across these indications. Signatures described previously for immune checkpoint inhibitors also failed to validate. At the pathway level, significant heterogeneity is observed between indications, in particular within the PD-L1+ tumors. mUC and NSCLC are molecularly aligned, with cell cycle and DNA damage repair genes associated with response in PD-L1- tumors. At the gene level, the CDK4/6 inhibitor CDKN2A is identified as a significant transcriptional correlate of response, highlighting the association of non-immune pathways to the outcome of checkpoint blockade. This cross-indication analysis reveals molecular heterogeneity between mUC, NSCLC and RCC tumors, suggesting that indication-specific molecular approaches should be prioritized to formulate treatment strategies.

Published
2021

13. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity

Author

Krishnamurty, Akshay T., Shyer, Justin A., Thai, Minh, Gandham, Vineela, Buechler, Matthew B., Yang, Yeqing Angela, Pradhan, Rachana N., Wang, Amber W., Sanchez, Patricia L., Qu, Yan, Breart, Beatrice, Chalouni, Cécile, Dunlap, Debra, Ziai, James, Elstrott, Justin, Zacharias, Neelie, Mao, Weiguang, Rowntree, Rebecca K., Sadowsky, Jack, Lewis, Gail D., Pillow, Thomas H., Nabet, Barzin Y., Banchereau, Romain, Tam, Lucinda, Caothien, Roger, Bacarro, Natasha, Roose-Girma, Merone, Modrusan, Zora, Mariathasan, Sanjeev, Müller, Sören, and Turley, Shannon J.

Published
2022
Full Text
View/download PDF

14. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Author

Powles, Thomas, Kockx, Mark, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Szabados, Bernadett, Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, van Dam, Pieter-Jan, Stanoeva, Diana, Daelemans, Sofie, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Banchereau, Romain, and Castellano, Daniel

Published
2023
Full Text
View/download PDF

15. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer

Author

Salomé, Bérengère, Sfakianos, John P., Ranti, Daniel, Daza, Jorge, Bieber, Christine, Charap, Andrew, Hammer, Christian, Banchereau, Romain, Farkas, Adam M., Ruan, Dan Fu, Izadmehr, Sudeh, Geanon, Daniel, Kelly, Geoffrey, de Real, Ronaldo M., Lee, Brian, Beaumont, Kristin G., Shroff, Sanjana, Wang, Yuanshuo A., Wang, Ying-chih, Thin, Tin Htwe, Garcia-Barros, Monica, Hegewisch-Solloa, Everardo, Mace, Emily M., Wang, Li, O’Donnell, Timothy, Chowell, Diego, Fernandez-Rodriguez, Ruben, Skobe, Mihaela, Taylor, Nicole, Kim-Schulze, Seunghee, Sebra, Robert P., Palmer, Doug, Clancy-Thompson, Eleanor, Hammond, Scott, Kamphorst, Alice O., Malmberg, Karl-Johan, Marcenaro, Emanuela, Romero, Pedro, Brody, Rachel, Viard, Mathias, Yuki, Yuko, Martin, Maureen, Carrington, Mary, Mehrazin, Reza, Wiklund, Peter, Mellman, Ira, Mariathasan, Sanjeev, Zhu, Jun, Galsky, Matthew D., Bhardwaj, Nina, and Horowitz, Amir

Published
2022
Full Text
View/download PDF

16. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Author

Szabados, Bernadett, Kockx, Mark, Assaf, Zoe June, van Dam, Pieter-Jan, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, Tyson, Charlotte, Stanoeva, Diana, Daelemans, Sofie, Rombouts, Miche, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Sharma, Shruti, Aleshin, Alexey, Banchereau, Romain, Castellano, Daniel, and Powles, Thomas

Published
2022
Full Text
View/download PDF

17. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Author

Mariathasan, Sanjeev, Turley, Shannon J, Nickles, Dorothee, Castiglioni, Alessandra, Yuen, Kobe, Wang, Yulei, Kadel, Edward E, Koeppen, Hartmut, Astarita, Jillian L, Cubas, Rafael, Jhunjhunwala, Suchit, Banchereau, Romain, Yang, Yagai, Guan, Yinghui, Chalouni, Cecile, Ziai, James, Şenbabaoğlu, Yasin, Santoro, Stephen, Sheinson, Daniel, Hung, Jeffrey, Giltnane, Jennifer M, Pierce, Andrew A, Mesh, Kathryn, Lianoglou, Steve, Riegler, Johannes, Carano, Richard AD, Eriksson, Pontus, Höglund, Mattias, Somarriba, Loan, Halligan, Daniel L, van der Heijden, Michiel S, Loriot, Yohann, Rosenberg, Jonathan E, Fong, Lawrence, Mellman, Ira, Chen, Daniel S, Green, Marjorie, Derleth, Christina, Fine, Gregg D, Hegde, Priti S, Bourgon, Richard, and Powles, Thomas

Subjects
Urothelium, CD8-Positive T-Lymphocytes, Fibroblasts, Animals, Humans, Mice, Urologic Neoplasms, Neoplasm Metastasis, Disease Models, Animal, Collagen, Transforming Growth Factor beta, Antibodies, Antibodies, Monoclonal, Antigens, Neoplasm, Treatment Outcome, Immunotherapy, Cohort Studies, Signal Transduction, Drug Resistance, Neoplasm, Phenotype, Mutation, Tumor Microenvironment, Antibodies, Monoclonal, Humanized, Cell Cycle Checkpoints, B7-H1 Antigen, Monoclonal, Humanized, Antigens, Neoplasm, Disease Models, Animal, Drug Resistance, General Science & Technology
Abstract

Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer. However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here we examined tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent (atezolizumab) and identified major determinants of clinical outcome. Response to treatment was associated with CD8+ T-effector cell phenotype and, to an even greater extent, high neoantigen or tumour mutation burden. Lack of response was associated with a signature of transforming growth factor β (TGFβ) signalling in fibroblasts. This occurred particularly in patients with tumours, which showed exclusion of CD8+ T cells from the tumour parenchyma that were instead found in the fibroblast- and collagen-rich peritumoural stroma; a common phenotype among patients with metastatic urothelial cancer. Using a mouse model that recapitulates this immune-excluded phenotype, we found that therapeutic co-administration of TGFβ-blocking and anti-PD-L1 antibodies reduced TGFβ signalling in stromal cells, facilitated T-cell penetration into the centre of tumours, and provoked vigorous anti-tumour immunity and tumour regression. Integration of these three independent biological features provides the best basis for understanding patient outcome in this setting and suggests that TGFβ shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T-cell infiltration.

Published
2018

18. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Author

Powles, Thomas, Yuen, Kobe C., Gillessen, Silke, Kadel, III, Edward E., Rathkopf, Dana, Matsubara, Nobuaki, Drake, Charles G., Fizazi, Karim, Piulats, Josep M., Wysocki, Piotr J., Buchschacher, Jr, Gary L., Alekseev, Boris, Mellado, Begoña, Karaszewska, Bogusława, Doss, Jennifer F., Rasuo, Grozdana, Datye, Asim, Mariathasan, Sanjeev, Williams, Patrick, and Sweeney, Christopher J.

Published
2022
Full Text
View/download PDF

19. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer

Author

Khan, Zia, Di Nucci, Flavia, Kwan, Antonia, Hammer, Christian, Mariathasan, Sanjeev, Rouilly, Vincent, Carroll, Jonathan, Fontes, Magnus, Acosta, Sergio Ley, Guardino, Ellie, Chen-Harris, Haiyin, Bhangale, Tushar, Mellman, Ira, Rosenberg, Jonathan, Powles, Thomas, Hunkapiller, Julie, Chandler, G. Scott, and Albert, Matthew L.

Published
2020

20. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Author

Powles, Thomas, Assaf, Zoe June, Davarpanah, Nicole, Banchereau, Romain, Szabados, Bernadett E., Yuen, Kobe C., Grivas, Petros, Hussain, Maha, Oudard, Stephane, Gschwend, Jürgen E., Albers, Peter, Castellano, Daniel, Nishiyama, Hiroyuki, Daneshmand, Siamak, Sharma, Shruti, Zimmermann, Bernhard G., Sethi, Himanshu, Aleshin, Alexey, Perdicchio, Maurizio, Zhang, Jingbin, Shames, David S., Degaonkar, Viraj, Shen, Xiaodong, Carter, Corey, Bais, Carlos, Bellmunt, Joaquim, and Mariathasan, Sanjeev

Published
2021
Full Text
View/download PDF

21. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

Author

Motzer, Robert J., Banchereau, Romain, Hamidi, Habib, Powles, Thomas, McDermott, David, Atkins, Michael B., Escudier, Bernard, Liu, Li-Fen, Leng, Ning, Abbas, Alexander R., Fan, Jinzhen, Koeppen, Hartmut, Lin, Jennifer, Carroll, Susheela, Hashimoto, Kenji, Mariathasan, Sanjeev, Green, Marjorie, Tayama, Darren, Hegde, Priti S., Schiff, Christina, Huseni, Mahrukh A., and Rini, Brian

Published
2020
Full Text
View/download PDF

23. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Author

Galsky, Matthew D, Arija, José Ángel Arranz, Bamias, Aristotelis, Davis, Ian D, De Santis, Maria, Kikuchi, Eiji, Garcia-del-Muro, Xavier, De Giorgi, Ugo, Mencinger, Marina, Izumi, Kouji, Panni, Stefano, Gumus, Mahmut, Özgüroğlu, Mustafa, Kalebasty, Arash Rezazadeh, Park, Se Hoon, Alekseev, Boris, Schutz, Fabio A, Li, Jian-Ri, Ye, Dingwei, Vogelzang, Nicholas J, Bernhard, Sandrine, Tayama, Darren, Mariathasan, Sanjeev, Mecke, Almut, Thåström, AnnChristine, and Grande, Enrique

Published
2020
Full Text
View/download PDF

24. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Author

Balar, Arjun, Galsky, Matthew, Rosenberg, Jonathan, Powles, Thomas, Petrylak, Daniel, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose, Dawson, Nancy, van der Heijden, Michiel, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta, Joseph, Richard, Drakaki, Alexandra, Vaishampayan, Ulka, Sridhar, Srikala, Quinn, David, Durán, Ignacio, Shaffer, David, Eigl, Bernhard, Grivas, Petros, Yu, Evan, Li, Shi, Kadel, Edward, Boyd, Zachary, Bourgon, Richard, Hegde, Priti, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale, Fine, Gregg, and Bajorin, Dean

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, B7-H1 Antigen, Biomarkers, Tumor, Carcinoma, Transitional Cell, Cisplatin, Contraindications, Female, Humans, Infusions, Intravenous, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Middle Aged, Response Evaluation Criteria in Solid Tumors, Urologic Neoplasms
Abstract

BACKGROUND: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients. METHODS: For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652. FINDINGS: Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients. INTERPRETATION: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer. FUNDING: F Hoffmann-La Roche, Genentech.

Published
2017

25. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

Author

Yuen, Kobe C., Liu, Li-Fen, Gupta, Vinita, Madireddi, Shravan, Keerthivasan, Shilpa, Li, Congfen, Rishipathak, Deepali, Williams, Patrick, Kadel, Edward E., III, Koeppen, Harmut, Chen, Ying-Jiun, Modrusan, Zora, Grogan, Jane L., Banchereau, Romain, Leng, Ning, Thastrom, Ann Christine, Shen, Xiadong, Hashimoto, Kenji, Tayama, Darren, van der Heijden, Michiel S., Rosenberg, Jonathan E., McDermott, David F., Powles, Thomas, Hegde, Priti S., Huseni, Mahrukh A., and Mariathasan, Sanjeev

Subjects
Interleukin-8 -- Health aspects, Metastasis -- Drug therapy -- Patient outcomes, Bladder cancer -- Drug therapy -- Patient outcomes, Apoptotic proteins -- Health aspects, Carcinoma, Renal cell -- Drug therapy -- Patient outcomes, Monoclonal antibodies -- Patient outcomes -- Health aspects, Biological sciences, Health
Abstract

Although elevated plasma interleukin-8 (pIL-8) has been associated with poor outcome to immune checkpoint blockade.sup.1, this has not been comprehensively evaluated in large randomized studies. Here we analyzed circulating pIL-8 and IL8 gene expression in peripheral blood mononuclear cells and tumors of patients treated with atezolizumab (anti-PD-L1 monoclonal antibody) from multiple randomized trials representing 1,445 patients with metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma. High levels of IL-8 in plasma, peripheral blood mononuclear cells and tumors were associated with decreased efficacy of atezolizumab in patients with mUC and metastatic renal cell carcinoma, even in tumors that were classically CD8.sup.+ T cell inflamed. Low baseline pIL-8 in patients with mUC was associated with increased response to atezolizumab and chemotherapy. Patients with mUC who experienced on-treatment decreases in pIL-8 exhibited improved overall survival when treated with atezolizumab but not with chemotherapy. Single-cell RNA sequencing of the immune compartment showed that IL8 is primarily expressed in circulating and intratumoral myeloid cells and that high IL8 expression is associated with downregulation of the antigen-presentation machinery. Therapies that can reverse the impacts of IL-8-mediated myeloid inflammation will be essential for improving outcomes of patients treated with immune checkpoint inhibitors. In a retrospective analysis of data from three clinical trials, increased baseline peripheral and tumor IL-8 levels were associated with worse clinical outcomes in patients with metastatic urothelial carcinoma and metastatic renal cell carcinoma treated with anti-PD-L1 therapy., Author(s): Kobe C. Yuen [sup.1] , Li-Fen Liu [sup.1] , Vinita Gupta [sup.1] , Shravan Madireddi [sup.1] , Shilpa Keerthivasan [sup.1] , Congfen Li [sup.1] , Deepali Rishipathak [sup.1] , [...]

Published
2020
Full Text
View/download PDF

26. Peripheral T cell expansion predicts tumour infiltration and clinical response

Author

Wu, Thomas D., Madireddi, Shravan, de Almeida, Patricia E., Banchereau, Romain, Chen, Ying-Jiun J., Chitre, Avantika S., Chiang, Eugene Y., Iftikhar, Hina, O’Gorman, William E., Au-Yeung, Amelia, Takahashi, Chikara, Goldstein, Leonard D., Poon, Chungkee, Keerthivasan, Shilpa, de Almeida Nagata, Denise E., Du, Xiangnan, Lee, Hyang-Mi, Banta, Karl L., Mariathasan, Sanjeev, Das Thakur, Meghna, Huseni, Mahrukh A., Ballinger, Marcus, Estay, Ivette, Caplazi, Patrick, Modrusan, Zora, Delamarre, Lélia, Mellman, Ira, Bourgon, Richard, and Grogan, Jane L.

Published
2020
Full Text
View/download PDF

27. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Author

Bamias, Aristotelis, primary, Davis, Ian D, additional, Galsky, Matthew D, additional, Arranz, José Á, additional, Kikuchi, Eiji, additional, Grande, Enrique, additional, del Muro, Xavier Garcia, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Schutz, Fabio A, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Panni, Stefano, additional, Gumus, Mahmut, additional, Özgüroğlu, Mustafa, additional, Mariathasan, Sanjeev, additional, Poloz, Yekaterina, additional, Bene-Tchaleu, Fabiola, additional, Lee, Chooi, additional, Bernhard, Sandrine, additional, and De Santis, Maria, additional

Published
2023
Full Text
View/download PDF

28. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Author

Grande, Enrique, primary, Arranz, José Á, additional, De Santis, Maria, additional, Bamias, Aristotelis, additional, Kikuchi, Eiji, additional, del Muro, Xavier Garcia, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Schutz, Fabio A, additional, Puente, Javier, additional, Li, Jian-Ri, additional, O'Donnell, Peter H, additional, Kalebasty, Arash Rezazadeh, additional, Ye, Dingwei, additional, Mariathasan, Sanjeev, additional, Bene-Tchaleu, FabioIa, additional, Bernhard, Sandrine, additional, Lee, Chooi, additional, Davis, Ian D, additional, and Galsky, Matthew D, additional

Published
2023
Full Text
View/download PDF

31. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Author

Powles, Thomas, Durán, Ignacio, van der Heijden, Michiel S, Loriot, Yohann, Vogelzang, Nicholas J, De Giorgi, Ugo, Oudard, Stéphane, Retz, Margitta M, Castellano, Daniel, Bamias, Aristotelis, Fléchon, Aude, Gravis, Gwenaëlle, Hussain, Syed, Takano, Toshimi, Leng, Ning, Kadel, Edward E, III, Banchereau, Romain, Hegde, Priti S, Mariathasan, Sanjeev, Cui, Na, Shen, Xiaodong, Derleth, Christina L, Green, Marjorie C, and Ravaud, Alain

Published
2018
Full Text
View/download PDF

32. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Author

Powles, Thomas, Kockx, Mark, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Szabados, Bernadett, Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, van Dam, Pieter-Jan, Stanoeva, Diana, Daelemans, Sofie, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Banchereau, Romain, and Castellano, Daniel

Published
2019
Full Text
View/download PDF

36. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay

Author

Powles, Thomas, primary, Young, Amanda, additional, Nimeiri, Halla, additional, Madison, Russell W., additional, Fine, Alexander, additional, Zollinger, Daniel R., additional, Huang, Yanmei, additional, Xu, Chang, additional, Gjoerup, Ole V., additional, Aushev, Vasily N., additional, Wu, Hsin-Ta, additional, Aleshin, Alexey, additional, Carter, Corey, additional, Davarpanah, Nicole, additional, Degaonkar, Viraj, additional, Gupta, Pratyush, additional, Mariathasan, Sanjeev, additional, Schleifman, Erica, additional, Assaf, Zoe June, additional, Oxnard, Geoffrey, additional, and Hegde, Priti S., additional

Published
2023
Full Text
View/download PDF

37. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

Author

Powles, Thomas, primary, Assaf, Zoe June, additional, Degaonkar, Viraj, additional, Grivas, Petros, additional, Hussain, Maha, additional, Oudard, Stephane, additional, Gschwend, Jürgen E., additional, Albers, Peter, additional, Castellano, Daniel, additional, Nishiyama, Hiroyuki, additional, Daneshmand, Siamak, additional, Sharma, Shruti, additional, Sethi, Himanshu, additional, Aleshin, Alexey, additional, Shi, Yi, additional, Davarpanah, Nicole, additional, Carter, Corey, additional, Bellmunt, Joaquim, additional, and Mariathasan, Sanjeev, additional

Published
2023
Full Text
View/download PDF

39. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Author

Rosenberg, Jonathan E, Hoffman-Censits, Jean, Powles, Tom, van der Heijden, Michiel S, Balar, Arjun V, Necchi, Andrea, Dawson, Nancy, O'Donnell, Peter H, Balmanoukian, Ani, Loriot, Yohann, Srinivas, Sandy, Retz, Margitta M, Grivas, Petros, Joseph, Richard W, Galsky, Matthew D, Fleming, Mark T, Petrylak, Daniel P, Perez-Gracia, Jose Luis, Burris, Howard A, Castellano, Daniel, Canil, Christina, Bellmunt, Joaquim, Bajorin, Dean, Nickles, Dorothee, Bourgon, Richard, Frampton, Garrett M, Cui, Na, Mariathasan, Sanjeev, Abidoye, Oyewale, Fine, Gregg D, and Dreicer, Robert

Published
2016
Full Text
View/download PDF

41. Supplementary Fig 1 from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer

Author

Wagle, Marie-Claire, primary, Castillo, Joseph, primary, Srinivasan, Shrividhya, primary, Holcomb, Thomas, primary, Yuen, Kobe C., primary, Kadel, Edward E., primary, Mariathasan, Sanjeev, primary, Halligan, Daniel L., primary, Carr, Adrian R., primary, Bylesjo, Max, primary, McAdam, Paul R., primary, Lynagh, Sarah, primary, Marien, Koen M., primary, Kockx, Mark, primary, Waumans, Yannick, primary, Huang, Shih-Min A., primary, Lackner, Mark R., primary, and Mounir, Zineb, primary

Published
2023
Full Text
View/download PDF

42. Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade

Author

Patil, Namrata S., primary, Srivats, Shyam, additional, Choi, Yoonha, additional, Guan, Xiangnan, additional, Nabet, Barzin, additional, McGinnis, Lisa, additional, Chiang, Eugene, additional, Dunkle, Alexis, additional, O’Gorman, Bill, additional, Chang, Patrick S., additional, Hu, Ruozhen, additional, Silva, John, additional, Han, Joy, additional, Au-Yeung, Amelia, additional, Takahashi, Chikara, additional, Molden, Nandini, additional, Daggumati, Pallavi, additional, Connolly, Wendy, additional, Johnson, Melissa, additional, Abreu, Delvys Rodriguez, additional, Cho, Byoung Chul, additional, Italiano, Antoine, additional, Gil-Bazo, Ignacio, additional, Felip, Enriqueta, additional, Mellman, Ira, additional, Meng, Raymond, additional, Mariathasan, Sanjeev, additional, Johnston, Robert, additional, and Shames, David S., additional

Published
2023
Full Text
View/download PDF

44. Data from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer

Author

Wagle, Marie-Claire, primary, Castillo, Joseph, primary, Srinivasan, Shrividhya, primary, Holcomb, Thomas, primary, Yuen, Kobe C., primary, Kadel, Edward E., primary, Mariathasan, Sanjeev, primary, Halligan, Daniel L., primary, Carr, Adrian R., primary, Bylesjo, Max, primary, McAdam, Paul R., primary, Lynagh, Sarah, primary, Marien, Koen M., primary, Kockx, Mark, primary, Waumans, Yannick, primary, Huang, Shih-Min A., primary, Lackner, Mark R., primary, and Mounir, Zineb, primary

Published
2023
Full Text
View/download PDF

45. Abstract 3362: Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay

Author

Sweeney, Christopher, primary, Xu, Chang, additional, He, Jie, additional, Young, Amanda, additional, Robertson, Alexander, additional, Petry, Russell, additional, Zollinger, Daniel, additional, Fine, Alexander, additional, Peterman, Neil, additional, Polisecki, Eliana, additional, Warner, Tyler, additional, Yuen, Kobe, additional, Huang, Yanmei, additional, Assaf, Zoe, additional, Graf, Ryon, additional, Mariathasan, Sanjeev, additional, Hegde, Priti, additional, Fabrizio, David, additional, and Powles, Thomas, additional

Published
2023
Full Text
View/download PDF

46. Supplementary Tables from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer

Author

Wagle, Marie-Claire, primary, Castillo, Joseph, primary, Srinivasan, Shrividhya, primary, Holcomb, Thomas, primary, Yuen, Kobe C., primary, Kadel, Edward E., primary, Mariathasan, Sanjeev, primary, Halligan, Daniel L., primary, Carr, Adrian R., primary, Bylesjo, Max, primary, McAdam, Paul R., primary, Lynagh, Sarah, primary, Marien, Koen M., primary, Kockx, Mark, primary, Waumans, Yannick, primary, Huang, Shih-Min A., primary, Lackner, Mark R., primary, and Mounir, Zineb, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Data from Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Author

Petrylak, Daniel P., primary, Loriot, Yohann, primary, Shaffer, David R., primary, Braiteh, Fadi, primary, Powderly, John, primary, Harshman, Lauren C., primary, Conkling, Paul, primary, Delord, Jean-Pierre, primary, Gordon, Michael, primary, Kim, Joseph W., primary, Sarkar, Indrani, primary, Yuen, Kobe, primary, Kadel, Edward E., primary, Mariathasan, Sanjeev, primary, O'Hear, Carol, primary, Narayanan, Sujata, primary, Fassò, Marcella, primary, Carroll, Susheela, primary, and Powles, Thomas, primary

Published
2023
Full Text
View/download PDF

48. Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.

Author

Bamias, Aristotelis, primary, Davis, Ian D., additional, Galsky, Matt D., additional, Arranz Arija, Jose Angel, additional, Kikuchi, Eiji, additional, Grande, Enrique, additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Bene-Tchaleu, Fabiola, additional, Mariathasan, Sanjeev, additional, Lee, Chooi Peng, additional, Bernhard, Sandrine, additional, and De Santis, Maria, additional

Published
2023
Full Text
View/download PDF

49. Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.

Author

Galsky, Matt D., primary, Arranz Arija, Jose Angel, additional, De Santis, Maria, additional, Davis, Ian D., additional, Bamias, Aristotelis, additional, Kikuchi, Eiji, additional, Garcia del Muro, Xavier, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Puente, Javier, additional, Li, Jian-Ri, additional, O'Donnell, Peter H., additional, Bernhard, Sandrine, additional, Lee, Chooi Peng, additional, Bene-Tchaleu, Fabiola, additional, Mariathasan, Sanjeev, additional, and Grande, Enrique, additional

Published
2023
Full Text
View/download PDF

50. Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

Author

Yuen, Kobe C., Liu, Li-Fen, Gupta, Vinita, Madireddi, Shravan, Keerthivasan, Shilpa, Li, Congfen, Rishipathak, Deepali, Williams, Patrick, Kadel, III, Edward E., Koeppen, Hartmut, Chen, Ying-Jiun, Modrusan, Zora, Grogan, Jane L., Banchereau, Romain, Leng, Ning, Thastrom, AnnChristine, Shen, Xiadong, Hashimoto, Kenji, Tayama, Darren, van der Heijden, Michiel S., Rosenberg, Jonathan E., McDermott, David F., Powles, Thomas, Hegde, Priti S., Huseni, Mahrukh A., and Mariathasan, Sanjeev

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results